SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001437749-18-022256
Filing Date
2018-12-19
Accepted
2018-12-19 10:34:38
Documents
1
Period of Report
2018-12-17

Document Format Files

Seq Description Document Type Size
1 FORM 3 rdgdoc.html 3  
1 FORM 3 rdgdoc.xml 3 1413
  Complete submission text file 0001437749-18-022256.txt   2878
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 4995 BRADENTON AVENUE, SUITE 240 DUBLIN OH 43017
Business Address
Rosol Michael Stanley (Reporting) CIK: 0001762349 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 181242491